[{"id":"737bf8ac-224d-4890-9289-ef1407053b41","acronym":"VITAL","url":"https://clinicaltrials.gov/study/NCT02658487","created_at":"2021-01-18T12:56:58.878Z","updated_at":"2024-07-02T16:35:06.085Z","phase":"Phase 2","brief_title":"Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia","source_id_and_acronym":"NCT02658487 - VITAL","lead_sponsor":"Vanderbilt-Ingram Cancer Center","biomarkers":" SRC","pipe":"","alterations":" ","tags":["SRC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Qinprezo (vosaroxin) • Starasid (cytarabine ocfosfate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 04/01/2019","primary_completion_date":" 04/01/2019","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-05-03"},{"id":"3689be87-0347-452c-86b7-798918118dc4","acronym":"","url":"https://clinicaltrials.gov/study/NCT00423735","created_at":"2021-01-18T01:29:26.895Z","updated_at":"2024-07-02T16:36:57.723Z","phase":"Phase 2","brief_title":"Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma","source_id_and_acronym":"NCT00423735","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KIT • SRC","pipe":"","alterations":" ","tags":["KIT • SRC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib"],"overall_status":"Completed","enrollment":" Enrollment 64","initiation":"Initiation: 01/24/2007","start_date":" 01/24/2007","primary_txt":" Primary completion: 03/09/2011","primary_completion_date":" 03/09/2011","study_txt":" Completion: 09/04/2018","study_completion_date":" 09/04/2018","last_update_posted":"2019-07-24"}]